强直性脊柱炎患者慢性病管理护理专家建议(2019版)

2020-05-30 中国风湿免疫科相关专家小组(统称) 中华风湿病学杂志.2020,24(5):292-296.

AS作为一种慢性炎症性自身免疫病,好发于青壮年男性,具有患病率高、致残率高、病程长、易反复、治疗费用高等特点,严重影响患者的身心健康及生活质量。为了更好地指导相关专业人员对AS患者进行慢性病管理,风湿

中文标题:

强直性脊柱炎患者慢性病管理护理专家建议(2019版)

发布日期:

2020-05-30

简要介绍:

AS作为一种慢性炎症性自身免疫病,好发于青壮年男性,具有患病率高、致残率高、病程长、易反复、治疗费用高等特点,严重影响患者的身心健康及生活质量。为了更好地指导相关专业人员对AS患者进行慢性病管理,风湿免疫疾病慢病管理全国护理协作组成立了由68位护理专家组成的小组,对AS患者的慢性病管理做出了共识建议。本共识包括15条,分别针对AS慢性病管理目标、多学科合作、自我管理、评估及自我评估、康复训练、药物管理、疼痛管理、疲劳管理、性功能管理等给出了建议。

下载附件:

(因为版权问题,不支持下载)

评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1235615, encodeId=06311235615c5, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07a75680560, createdName=ms6000000456984754, createdTime=Sat Jul 30 11:58:36 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179341, encodeId=675111e934131, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca62642771, createdName=532690445, createdTime=Fri Dec 31 15:34:25 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068161, encodeId=4def10681616f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15695243, createdName=ms9000000829702817, createdTime=Mon Nov 08 16:50:14 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003920, encodeId=c57a1003920fe, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210730/857f21059c6948cebb485e06824d6de1/48ebf5ddeae54c2b9477f92f22df37d0.jpg, createdBy=23805560352, createdName=ms1000000152130845, createdTime=Fri Jul 30 16:16:42 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997321, encodeId=9d3199e3212e, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9695535194, createdName=ms6000000573240023, createdTime=Wed Jul 07 21:29:39 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2022-07-30 ms6000000456984754

    非常好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1235615, encodeId=06311235615c5, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07a75680560, createdName=ms6000000456984754, createdTime=Sat Jul 30 11:58:36 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179341, encodeId=675111e934131, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca62642771, createdName=532690445, createdTime=Fri Dec 31 15:34:25 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068161, encodeId=4def10681616f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15695243, createdName=ms9000000829702817, createdTime=Mon Nov 08 16:50:14 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003920, encodeId=c57a1003920fe, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210730/857f21059c6948cebb485e06824d6de1/48ebf5ddeae54c2b9477f92f22df37d0.jpg, createdBy=23805560352, createdName=ms1000000152130845, createdTime=Fri Jul 30 16:16:42 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997321, encodeId=9d3199e3212e, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9695535194, createdName=ms6000000573240023, createdTime=Wed Jul 07 21:29:39 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-12-31 532690445

    想学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1235615, encodeId=06311235615c5, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07a75680560, createdName=ms6000000456984754, createdTime=Sat Jul 30 11:58:36 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179341, encodeId=675111e934131, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca62642771, createdName=532690445, createdTime=Fri Dec 31 15:34:25 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068161, encodeId=4def10681616f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15695243, createdName=ms9000000829702817, createdTime=Mon Nov 08 16:50:14 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003920, encodeId=c57a1003920fe, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210730/857f21059c6948cebb485e06824d6de1/48ebf5ddeae54c2b9477f92f22df37d0.jpg, createdBy=23805560352, createdName=ms1000000152130845, createdTime=Fri Jul 30 16:16:42 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997321, encodeId=9d3199e3212e, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9695535194, createdName=ms6000000573240023, createdTime=Wed Jul 07 21:29:39 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-11-08 ms9000000829702817

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1235615, encodeId=06311235615c5, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07a75680560, createdName=ms6000000456984754, createdTime=Sat Jul 30 11:58:36 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179341, encodeId=675111e934131, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca62642771, createdName=532690445, createdTime=Fri Dec 31 15:34:25 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068161, encodeId=4def10681616f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15695243, createdName=ms9000000829702817, createdTime=Mon Nov 08 16:50:14 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003920, encodeId=c57a1003920fe, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210730/857f21059c6948cebb485e06824d6de1/48ebf5ddeae54c2b9477f92f22df37d0.jpg, createdBy=23805560352, createdName=ms1000000152130845, createdTime=Fri Jul 30 16:16:42 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997321, encodeId=9d3199e3212e, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9695535194, createdName=ms6000000573240023, createdTime=Wed Jul 07 21:29:39 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-30 ms1000000152130845

    想看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1235615, encodeId=06311235615c5, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07a75680560, createdName=ms6000000456984754, createdTime=Sat Jul 30 11:58:36 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179341, encodeId=675111e934131, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca62642771, createdName=532690445, createdTime=Fri Dec 31 15:34:25 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068161, encodeId=4def10681616f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffe15695243, createdName=ms9000000829702817, createdTime=Mon Nov 08 16:50:14 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003920, encodeId=c57a1003920fe, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210730/857f21059c6948cebb485e06824d6de1/48ebf5ddeae54c2b9477f92f22df37d0.jpg, createdBy=23805560352, createdName=ms1000000152130845, createdTime=Fri Jul 30 16:16:42 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997321, encodeId=9d3199e3212e, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9695535194, createdName=ms6000000573240023, createdTime=Wed Jul 07 21:29:39 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-07 ms6000000573240023

    非常好

    0

拓展阅读

2010 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议

中国风湿免疫科相关专家小组(统称) · 2010-06-30

2010版 强直性脊柱炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-08-01

2010年更新的ASAS/ EULAR对强直性脊柱炎的治疗指南意见

国际评估强直性脊柱炎工作组(ASAS,ASsessment in Ankylosing Spondylitis international Society) · 2011-01-01

2011 NICE 强直性脊柱炎--戈利木单抗用药指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-08-24

2012 强直性脊柱炎的诊断与治疗骨科专家共识

中国骨科相关专家小组(统称) · 2012-09-01

依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议(2013)

中国风湿免疫科相关专家小组(统称) · 2013-05-14